Abstract
There is now scientific evidence of genetically driven skin barrier anomalies in atopic patients. These barrier anomalies facilitate sustained antigen ingress through the defective barrier, which can bring about a Th2-dominant response. It enhances the transepidermal water loss, resulting in dry skin and leading to the release of pre-formed pro-inflammatory cytokines and to a cascade of events ending up in inflammation.
There is scientific evidence indicating that skin barrier dysfunction plays a prominent role in the development and perpetuation of atopic dermatitis (AD), the "outside-to-inside" view of AD pathogenesis. Moisturizers have a pivotal role in improving and maintaining the skin barrier function and in reducing skin susceptibility to irritants. These emollients are a standard of care, the mainstay of AD therapy, and useful for both prevention and maintenance therapy.
Regular use of emollients has a short-and long-term steroid-sparing effect in mild-tomoderate AD. They should be recommended in adequate amounts and used liberally and frequently in atopic patients. Recently, "Barrier-repair therapeutics" has entered the market, generally as devices, requiring prescriptions (510k-cleared moisturizers). Although this new class of moisturizers has shown excellent performance, efficacy, and safety, we could raise questions about their superiority over a well-crafted traditional, petrolatum-based OTC emollient, as we have been unable to find any scientific evidence to support this claim. In addition, there is currently no definition for "barrier-repair products," raising the additional question of whether such presently available products could justify such a category.
The "outside-to-inside" view of atopic dermatitis and its therapeutic implications
Until recently, it was thought that the pathogenic mechanism of atopic dermatitis (AD) was initiated by immune dysfunction leading to Th1/Th2 cell dysregulation, IgE production, mast cell hyperactivity, and dendritic cell signaling. Although both defective epidermal permeability that causes dry skin and leads to a predisposition to secondary infection are well-recognized features of AD, these conditions have been widely assumed to reflect downstream consequences of a primary immunologic abnormality (the historical "inside-tooutside" view of AD pathogenesis). Accumulating evidence, however, now suggests that a primary defect in the stratum corneum may play a key role not only in initiating but also in perpetuating AD. This dysfunction of the barrier leads to the release of pre-formed proinflammatory cytokines and sets into motion a cascade of events that provoke and sustain disease activity (the "outside-to-inside" view of AD pathogenesis).
Two main mechanisms account for the outside-to-inside direction of events, that is to say, from the impaired barrier to the development of the inflammation. One is the release of a cytokine cascade that up-regulates lipid synthesis, lamellar body secretion, and epidermal proliferation aimed at the restoration of the barrier function and the initiation of inflammation. The other is the penetration of irritants, allergens, haptens, superantigens, and bacterial toxins.
Awareness of the primary role of the stratum corneum in the pathogenesis of AD, as well as in other inflammatory diseases, has opened up new therapeutic options and a new therapeutic concept: to treat not only the inflammation but also to restore the barrier. The historical origins of this concept derive from the numerous, innovative works of Elias and co-workers, which have been well presented in a 2001 paper with the catchy title, "Does the tail wag the dog?" 1 A further step in this direction was the development of a new pharmacologic approach aimed at barrier repair. It involves the delivery of balanced proportions of stratum corneum-specific lipids to assist in correcting this epidermal barrier dysfunction.
In a state of physiologic balance, the approximate proportions of the lipid component are predominantly composed of 50% ceramides, 25% cholesterol, and 10-20% free fatty acids. In AD, there is a decrease in all three key lipids, especially ceramides, which are found in both affected and non-affected skin. A lipid imbalance and inadequate amounts of ceramides contribute to defective formation of the corneocyte lipid envelope and lipid mortar, which correlate with increased transepidermal water loss and enhanced barrier permeability 2 .
These scientific findings have led to a second look at the use of moisturizers.
There has been a shift from traditional moisturizers towards ceramide-dominant physiological lipid-base barrier-repair topical emulsions. According to several reports 2 , these formulations focus on physiologic lipid replacement therapy, particularly ceramides, to restore the normal balance of the epidermal barrier. Compared with other emollients that form a more superficial occlusive barrier (e.g., petrolatum), ceramide-dominant moisturizers are thought to permeate the stratum corneum and to be synthesized in the keratinocytes, processed in the lamellar bodies, and secreted back into the stratum corneum, where they become a part of the dermal matrix.
In an extensive review by Elias 3 , the developer of barrier-repair therapeutics, he states:
"Typical emollient moisturizers, even if they provide some temporary relief through moisturization, actually degrade, rather than improve, barrier function, and by providing partial relief, they actually delay barrier repair." This, he claims, is in contrast to the use of corrective barrier repair creams that contain "sufficient quantities of all three key lipids that mediate barrier function (i.e., cholesterol, free fatty acids, and ceramides)…"
510(k)-cleared prescription moisturizers
These barrier-repair products to which Elias is referring are technically different from traditional over-the-counter (OTC) nonprescription moisturizers, because the Food and Drug The results showed that the cream was statistically more effective than vehicle in all outcomes. As could be expected, the authors' conclusions were: "…the cream is rapidly effective and safe as a non-steroidal monotherapy in mild to moderate AD, and it may be useful as a topical steroid sparing agent".
The third of the four multicenter studies that we found 12 was a randomized, double-blind, vehicle-controlled trial comprised of 142 patients aged 6 months to 12 years, whose treatment consisted of applying either the test substance or the vehicle 3 times per day. The primary endpoint for efficacy was the Investigator's Global Assessment (IGA) score for AD at day 22.
The secondary endpoints were patient/caregiver's assessment of pruritus, onset, duration of itch relief, the EASI score, and the need for rescue medication in the event of an AD flare.
The test substance (Atopiclair®) was found to be significantly more effective (P<. 0001) than the vehicle cream for the primary endpoint and for all the secondary endpoints in this cohort of infants and children.
The fourth multicenter double-blind, randomized, vehicle-controlled study on 60 pediatric patients 13 also showed a significant difference between the tested product (Atopiclair®) and the vehicle. This study consisted of a treatment period of 43 days. The test substance showed 80% improvement in the IGA score at day 22, compared with a score of 26.3% for the vehicle. This statistical significance was sustained until the end of the study. The authors' conclusions were that the product "may be considered as one of the available regimens effective in the treatment of mild-to-moderate AD in children and adolescents". An OTC moisturizer control group was again conspicuously missing.
The second prescription device cream, Mimyx®, contains a unique lamellar matrix of pharmaceutical emollient substances, including palmitoylethanolamine (PEA). PEA is a cannabinoid agonist that has antiinflammatory, antipruritic features and the capacity to inhibit mast cell activation. We are aware of at least one very large, multinational, multicenter, non-controlled prospective study 14 in which data on the effect of Mimyx® on 2456 patients from 525 centers were analyzed.
The study showed substantial relief of objective and subjective manifestations of AD. The intensities of symptoms were reduced (with a combined score reduction of 58% in the entire population), previously used topical corticosteroids were discontinued by 56% of all patients, and the average weekly application rate decreased by 62%.
The third prescription topical cream is the lipid-rich Eletone® emulsion. An investigatorblinded bilateral study 15 
Prescription moisturizers versus OTC moisturizers
All of the above-cited studies demonstrated that each tested product is safe and effective in treating AD, either as monotherapy or as adjuvant treatment together with other treatments.
Some of them compared the product to steroids, some to a topical immunomodulator, and others to vehicle alone. Even if they achieve the highest marks for objectivity, quality, and clinical value, it is impossible for them to claim that any of the prescription device moisturizers are superior to ordinary OTC moisturizers, because none of them compared the tested product to an ordinary non-prescription OTC emollient/moisturizer, which is inarguably much less expensive.
There are, however, at least 2 other studies that did compare prescription moisturizers with OTC emollients. One of them 16 compared a prescription moisturizer (Mimyx®) to a mineral oil, petrolatum, and paraffin OTC moisturizer that had been commercially available for over 100 years. This investigator-blinded research utilized a split-body model in 60 subjects (30 with mild eczema, 30 with moderate eczema) to examine effect of the two products in the treatment of eczema of the arms or legs. The subjects with mild eczema were asked to use the OTC moisturizer twice daily to the randomized right or left target limb and a prescription device to the other randomized target limb. In addition, 30 subjects with moderate eczema were asked to use the OTC moisturizer and 0.1% triamcinolone acetonide cream (TAC) twice daily to the randomized limb and a prescription device and TAC. All subjects with mild and moderate eczema were rated as being clear by the dermatologist investigator at the end of the study. Each target site limb was evaluated separately, and at no time point during the study (i.e., at week 1, 2, or 4) were there any statistically significant differences between the OTC and device moisturizer. The subject assessments also showed no statistically significant differences between the OTC and device moisturizer at any time point. The investigator concluded that parity was established in the treatment of mild-to-moderate eczema with both products that showed excellent results.
The other study that we found 17 
What should we recommend to our patients?
If there is any scientific, evidence-based support for the superiority of the prescription device moisturizers over well-crafted, traditional, petrolatum-based OTC emollients, we could not find it. The obvious $64,000 question would be, what should we recommend to our patients?
It seems that this pressing question will have to remain unanswered until more convincing evidence-based and unbiased information becomes available.
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Moisturizers for AD: Facts and controversies
 There is now scientific evidence of genetically driven skin barrier anomalies in atopic patients.
 These barrier anomalies facilitate sustained antigen ingress through the defective barrier which can bring about a Th2-dominant response. It enhances the transepidermal water loss, resulting in dry skin and leading to the release of preformed pro-inflammatory cytokines and to a cascade of events ending up in inflammation.
 There is scientific evidence indicating that skin barrier dysfunction plays a prominent role in the development and perpetuation of AD, the "outside-to-inside" view of AD pathogenesis.
 Moisturizers have a pivotal role in improving and maintaining the skin barrier function and reducing skin susceptibility to irritants 18 .
 Emollients are a standard of care, the mainstay of AD therapy, and useful for both prevention and maintenance therapy 18 .
 Regular use of emollients has a short-and long-term steroid-sparing effect in mild-tomoderate AD.
 Emollients should be recommended in adequate amounts and used liberally and frequently in atopic patients.
 The type of emollient best suited for this approach has not yet been delineated.
14  "Barrier-repair therapeutics" has recently entered the market as prescription 510k-cleared moisturizers.
 Although this new class of moisturizers has shown excellent performance, emphasizing efficacy and safety, there is no evidence to support their superiority over a well-crafted traditional, petrolatum-based OTC emollient.
 There is currently no definition for "barrier-repair products." It is unclear, if presently available products justify such a category. The issue is even more cloudy with the term "moisturizer," used for products which do not moisturize. This term was actually invented by Madison Avenue marketeers for promoting the simplistic idea that moistening the skin will keep it soft and flexible; however, there is currently no medical definition of these so called moisturizers or emollients.
 The approval of emollients , which do not contain demonstrably active ingredients different from "ordinary" emolients , as prescription devices seems to be a technicality that confuses the issue.
